Alessandro Mussa1, Kelly A Duffy2, Diana Carli1, Jessica R Griff2, Riccardo Fagiano1, Jonida Kupa2, Garrett M Brodeur3,4, Giovanni Battista Ferrero1, Jennifer M Kalish5,6,7. 1. Department of Public Health and Pediatric Sciences, University of Torino, Turin, Italy. 2. Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, USA. 3. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, USA. 4. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5. Division of Human Genetics, Children's Hospital of Philadelphia, Philadelphia, USA. kalishj@email.chop.edu. 6. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. kalishj@email.chop.edu. 7. Division of Human Genetics, Children's Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB, Rm 3028, Philadelphia, PA, 19104, USA. kalishj@email.chop.edu.
Abstract
PURPOSE: It is well documented that patients with Beckwith-Wiedemann spectrum (BWS) have a significantly higher risk of developing Wilms tumor (WT) than the general population. There has been little research on the timing of WT diagnosis in BWS in regard to optimizing suggested screening protocols. METHODS: A literature search was performed to identify all reports of patients with BWS and WT. These data were combined with unpublished data from patients in the authors' cohorts. Age at WT diagnosis was compared against data collected through the NIH Surveillance, Epidemiology, and End Results Program (SEER) registry. RESULTS: Patients with BWS had a significantly higher incidence of WT diagnoses between age 12 and 84 months compared to patients in the SEER registry. Patients with BWS and WT diagnosed through screening had significantly lower stages at diagnosis compared to patients with BWS that were not screened. CONCLUSIONS: Screening until age 7 years is effective in detecting close to 95% of all WT in patients with BWS.
PURPOSE: It is well documented that patients with Beckwith-Wiedemann spectrum (BWS) have a significantly higher risk of developing Wilms tumor (WT) than the general population. There has been little research on the timing of WT diagnosis in BWS in regard to optimizing suggested screening protocols. METHODS: A literature search was performed to identify all reports of patients with BWS and WT. These data were combined with unpublished data from patients in the authors' cohorts. Age at WT diagnosis was compared against data collected through the NIH Surveillance, Epidemiology, and End Results Program (SEER) registry. RESULTS:Patients with BWS had a significantly higher incidence of WT diagnoses between age 12 and 84 months compared to patients in the SEER registry. Patients with BWS and WT diagnosed through screening had significantly lower stages at diagnosis compared to patients with BWS that were not screened. CONCLUSIONS: Screening until age 7 years is effective in detecting close to 95% of all WT in patients with BWS.
Entities:
Keywords:
Beckwith–Wiedemann Syndrome; Cancer predisposition; Cancer screening; Wilms tumor
Authors: F Brioude; A Lacoste; I Netchine; M-P Vazquez; F Auber; G Audry; M Gauthier-Villars; L Brugieres; C Gicquel; Y Le Bouc; S Rossignol Journal: Horm Res Paediatr Date: 2013-12-04 Impact factor: 2.852
Authors: Elizabeth M Algar; Luke St Heaps; Artur Darmanian; Vinod Dagar; Dirk Prawitt; Greg B Peters; Felicity Collins Journal: Cancer Res Date: 2007-02-26 Impact factor: 12.701
Authors: W G Vaughan; D W Sanders; J L Grosfeld; D A Plumley; F J Rescorla; L R Scherer; K W West; P P Breitfeld Journal: J Pediatr Surg Date: 1995-07 Impact factor: 2.545
Authors: Alessandro Mussa; Kelly A Duffy; Diana Carli; Giovanni Battista Ferrero; Jennifer M Kalish Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167
Authors: Kelly A Duffy; Kelly L Trout; Jennifer M Gunckle; Shari McCullen Krantz; John Morris; Jennifer M Kalish Journal: Front Pediatr Date: 2021-12-14 Impact factor: 3.418
Authors: Kelly A Duffy; Kelly D Getz; Evan R Hathaway; Mallory E Byrne; Suzanne P MacFarland; Jennifer M Kalish Journal: Genes (Basel) Date: 2021-11-21 Impact factor: 4.096